Healthcare / BiotechnologyNasdaqGS
$3.14
-0.11 (-3.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-104.1M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$225M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-33.3%
↓Gross Margin
N/A
•Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-104.1M · FCF $-89.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | — | — | — | — | — | $0.00 | — | $115000.00 |
| Net Income | $-104.1M | $-104.1M | $-108.8M | $-117.5M | $-113.8M | $-86.1M | $-91.4M | $-21.1M |
| EBITDA | $-112.8M | $-112.8M | $-119.0M | $-125.8M | $-116.3M | $-84.6M | $-50.7M | $-21.9M |
| EPS | -1.41 | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 | — | — |
| Operating Margin | — | — | — | — | — | — | — | -19433.9% |
| Net Margin | — | — | — | — | — | — | — | -18327.0% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.24 | 0.24 | 0.20 | 0.32 | 0.22 | — | — | — |
| Current Ratio | 12.96 | 12.96 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-89.9M | $-89.9M | $-104.1M | $-114.3M | $-104.1M | $-73.0M | $-51.0M | $-20.3M |
| Returns | ||||||||
| ROE | -33.3% | -33.3% | -26.7% | -43.0% | -30.6% | -34.3% | -28.4% | 82.7% |
| Valuation | ||||||||
| P/B | 0.74 | 0.74 | 0.42 | 1.09 | 0.68 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | 11.9% | 11.9% | 33.3% | 8.0% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+80.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.60 → -1.41
Residual
+80.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.